1,027 results on '"Palareti, Gualtiero"'
Search Results
2. Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital
3. Machine learning approach for prediction of outcomes in anticoagulated patients with atrial fibrillation
4. DOACs use in extreme body-weighted patients: results from the prospective START-register
5. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events
6. D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results
7. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
8. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
9. Renin‐angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry
10. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry
11. Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
12. Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional study
13. D-Dimer Levels in Patients with Acute Venous Thromboembolism and Occult Cancer: TheDd-Neo Study
14. MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY
15. Corrigendum to “Machine learning approach for prediction of outcomes in anticoagulated patients with atrial fibrillation” [International Journal of Cardiology 407 (2024) 132088]
16. Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence
17. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
18. Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
19. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
20. The diagnostic procedure for subjects with suspected pulmonary embolism. A recent comparison among the recommendations available from the international guidelines
21. Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis
22. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs
23. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism
24. Sex Differences in Clinical Presentation of Lower Extremity Deep Vein Thrombosis.
25. Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience
26. LOW LEVELS OF DIRECT ORAL ANTICOAGULANTS AT STEADY STATE IN ATRIAL FIBRILLATION PATIENTS WHO LATER DEVELOP THROMBOTIC COMPLICATIONS; THE PROSPECTIVE MAS (MEASURE AND SEE) STUDY
27. D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications
28. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry
29. Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries
30. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event : systematic review and meta-analysis
31. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry)
32. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution
33. The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study
34. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
35. Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.
36. Management and 1-Year Outcome in Elderly Patients with Hip Fracture Surgery Receiving Anticoagulation (Warfarin or DOAc) or P2Y12 Antiplatelet Agents
37. Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study
38. Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry)
39. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry
40. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures
41. Venous Thromboembolism in Women of Childbearing Age: Insights from the START Registry
42. VENOUS THROMBOEMBOLISM SECONDARY TO HOSPITALIZATION FOR COVID-19 DISEASE: PATIENT MANAGEMENT AND LONG-TERM OUTCOMES
43. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation
44. Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding
45. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non–gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
46. Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study
47. COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from Apidulcis study
48. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial
49. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago
50. Italian intersociety consensus on DOAC use in internal medicine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.